Everest Medicines directors, major shareholder boost stakes

On December 12, 2025, Everest Medicines’ non-executive director Wei Fu, executive director and chairman Yifang Wu, executive director and CEO Yongqing Luo, and executive director and president Ian Ying Woo collectively purchased 846,659 ordinary shares on the market. The total consideration for these acquisitions exceeded HK$38,000,000, at an average price of approximately HK$45.01 per share.

In a further show of confidence, substantial shareholder CBC Group has committed to increasing its shareholding by up to an additional 1% over the next three to six months. This increase is subject to market conditions and regulatory compliance.

The board of Everest Medicines believes these voluntary share purchases by directors and CBC Group's undertaking underscore strong confidence in the company’s future prospects and long-term development. Shareholders and potential investors are advised to exercise caution when dealing in the company's securities.